hrp0084p3-814 | Endocrine Oncology | ESPE2015

Results of GH Treatment in Childhood Brain Tumours Survivors

Mazerkina Nadia , Gorelyshev Sergey , Geludkova Olga

Background: GH deficiency is the most common endocrine disorder in childhood brain tumours survivors.Objective and hypotheses: To examine results and safety of GH treatment in patients with childhood brain tumours.Method: 118 patients (72 craniopharyngioma, 29 medulloblastoma, 17 germ cell tumours) received hGH in the dose 0.03–0.034 mg/kg per day for 2.3±0.8 years. The mean chronological age at the start of the treatment...

hrp0092fc11.4 | Pituitary, Neuroendocrinology and Puberty Session 2 | ESPE2019

Whole Exome Sequencing in a Familial Case of Adamantinomatous Craniopharyngioma Revealed Two Hits Affecting Wnt-Signaling Pathway

Gorelyshev Alexander , Mazerkina Nadezhda , Vasilyev Evgeny , Petrov Vasily , Ryzhova Marina , Gorelyshev Sergey , Tiulpakov Anatoly

Background: Craniopharyngiomas (CPs) are benign brain tumours that intimately involve pituitary and, often, hypothalamus. Here, primary clinical conundrum is choosing between gross total resection and preserving endocrine functions. Robust predictors of recurrence are much needed, but require a deeper understanding of the molecular basis of CPs. Multiple studies show that CTNNB1 (β-catenin) somatic mutations drive the adamantinomatous subtype ...

hrp0092fc11.5 | Pituitary, Neuroendocrinology and Puberty Session 2 | ESPE2019

Survival, Endocrine Disorders and Quality of Life in 135 Children with Craniopharyngioma After Surgical or Combined Treatment

Mazerkina Nadia , Savateev Alexandre , Gorelyshev Sergey , Trunin Yuri , Golanov Andrey , Kutin Maxim , Kalinin Pavel , Konovalov Alexandre

Patients and Methods: We analyzed 135 primary operated craniopharyngioma (CP) patients and 75 CP patients, received radiotherapy/radiosurgery in 2005-2012. Neurologic, endocrine, visual functions, quality of life (QofL) and neuroimaging data before and after treatment were assessed.Patients were divided in 2 groups according to CP location: 48,5% endosellar (ESCP), and 51,5% suprasellar (SSCP). Surgical treatment included tumor e...